MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
common stock,...
$4,352,792
Proceeds from issuance of
common shares from atm,...
$347,549
Net cash provided by
financing activities
$4,700,341
Net increase in cash
$2,009,191
Canceled cashflow
$2,691,150
Stock-based compensation
$256,358
Accounts payable and
accrued expenses
$91,025
Advances on research and
development contract...
$49,087
Prepaid insurance
-$35,233
Net cash used in
operating activities
-$2,691,150
Canceled cashflow
$431,703
Other income
$125,951
Net loss
-$3,108,991
Canceled cashflow
$125,951
Interest receivable
$9,895
Change in fair value of
warrant liability
-$3,967
Research and development
$1,060,191
Operating expenses
$983,054
Salaries
$650,000
Insurance
$285,339
Stock-based compensation
$256,358
Back
Back
Cash Flow
source: myfinsight.com
Bone Biologics Corp (BBLGW)
Bone Biologics Corp (BBLGW)